Grifols (NASDAQ:GRFS) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut shares of Grifols (NASDAQ:GRFS) from a buy rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other research firms have also recently weighed in on GRFS. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average target price of $10.00.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $7.46 on Friday. Grifols has a 1 year low of $6.96 and a 1 year high of $9.90. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81. The company’s 50-day moving average is $7.67 and its 200 day moving average is $7.74. The stock has a market capitalization of $5.08 billion, a P/E ratio of 39.26, a P/E/G ratio of 0.27 and a beta of 0.70.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Armistice Capital LLC boosted its stake in Grifols by 23.8% during the fourth quarter. Armistice Capital LLC now owns 2,768,000 shares of the biotechnology company’s stock worth $25,881,000 after acquiring an additional 532,000 shares in the last quarter. Flat Footed LLC lifted its holdings in shares of Grifols by 26.5% during the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after purchasing an additional 287,867 shares during the last quarter. Tidal Investments LLC boosted its position in shares of Grifols by 9.8% in the 2nd quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after purchasing an additional 109,612 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Grifols by 15.4% in the 1st quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after purchasing an additional 104,850 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of Grifols by 13.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock worth $4,193,000 after buying an additional 72,037 shares during the last quarter.

About Grifols

Grifols SA is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products.

Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines.

Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing.